A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
← catalyst calendarNCT06393712 · readout in 355 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
200estimated
Sites
57
Countries
Australia, Canada, Netherlands +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-17 | actual | When the study began enrolling |
| Primary completion | 2027-08-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cerebral Amyloid Angiopathy
Interventions
- Drug: Placebo
- Drug: ALN-APP — also filed as mivelsiran
Primary outcome
what the primary-completion date above is the date OFDouble-blind Treatment Period: Annualized Rate of New Lobar Cerebral Microbleeds (CMBs) Assessed on Magnetic Resonance Imaging (MRI) of Brain in Patients with Sporadic Cerebral Amyloid Angiopathy (sCAA)
measured Up to 24 months
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed